Skip to content
10-Q

Quarterly Report

HALOZYME THERAPEUTICS, INC. HALO

0001159036-26-000068

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 118.61M sh
Shares Diluted Q1 2026 · Mar 31, 2026 122.88M sh
Shares Diluted Q1 2026 · Mar 31, 2025 126.64M sh
Capex Q1 2026 · Mar 31, 2026 $3.74M
Capex Q1 2026 · Mar 31, 2025 $950K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $180.08M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $154.22M
Long Term Debt Q1 2026 · Mar 31, 2026 $1.94B
Long Term Debt Q1 2026 · Dec 31, 2025 $2.14B
Short Term Debt Q1 2026 · Mar 31, 2026 $208.74M
Short Term Debt Q1 2026 · Dec 31, 2025 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $309.75M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $133.82M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $176.33M
Stockholders Equity Q1 2026 · Mar 31, 2026 $219.64M
Stockholders Equity Q1 2026 · Dec 31, 2025 $48.81M
Stockholders Equity Q1 2026 · Mar 31, 2025 $482.27M
Stockholders Equity Q1 2026 · Dec 31, 2024 $363.82M
Current Liabilities Q1 2026 · Mar 31, 2026 $363.21M
Current Liabilities Q1 2026 · Dec 31, 2025 $177.09M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.45B
Total Liabilities Q1 2026 · Dec 31, 2025 $2.48B
Current Assets Q1 2026 · Mar 31, 2026 $1B
Current Assets Q1 2026 · Dec 31, 2025 $825.21M
Total Assets Q1 2026 · Mar 31, 2026 $2.67B
Total Assets Q1 2026 · Dec 31, 2025 $2.53B
Eps Diluted Q1 2026 · Mar 31, 2026 $1.22
Eps Diluted Q1 2026 · Mar 31, 2025 $0.93
Eps Basic Q1 2026 · Mar 31, 2026 $1.27
Eps Basic Q1 2026 · Mar 31, 2025 $0.96
Sga Expense Q1 2026 · Mar 31, 2026 $57.88M
Sga Expense Q1 2026 · Mar 31, 2025 $42.36M
Rd Expense Q1 2026 · Mar 31, 2026 $25.56M
Rd Expense Q1 2026 · Mar 31, 2025 $14.8M
Net Income Q1 2026 · Mar 31, 2026 $150.05M
Net Income Q1 2026 · Mar 31, 2025 $118.1M
Operating Income Q1 2026 · Mar 31, 2026 $184.52M
Operating Income Q1 2026 · Mar 31, 2025 $141.54M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $79.24M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $48.4M
Revenue Q1 2026 · Mar 31, 2026 $376.71M
Revenue Q1 2026 · Mar 31, 2025 $264.86M